Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report report published on Saturday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Several other brokerages have also recently issued reports on TENX. Leerink Partners set a $20.00 price target on Tenax Therapeutics in a research report on Monday, March 10th. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Price Performance

Shares of TENX opened at $6.49 on Friday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89. The stock has a market cap of $25.73 million, a PE ratio of -1.22 and a beta of 2.20. The firm has a fifty day moving average price of $6.43 and a 200 day moving average price of $5.43.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.34. As a group, equities analysts expect that Tenax Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TENX. Geode Capital Management LLC lifted its position in Tenax Therapeutics by 32.4% in the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 5,964 shares during the period. Two Sigma Investments LP acquired a new stake in shares of Tenax Therapeutics in the 4th quarter valued at approximately $84,000. Millennium Management LLC purchased a new stake in shares of Tenax Therapeutics in the fourth quarter valued at approximately $166,000. Sphera Funds Management LTD. acquired a new position in Tenax Therapeutics during the third quarter worth $101,000. Finally, Janus Henderson Group PLC purchased a new position in Tenax Therapeutics in the fourth quarter worth $1,026,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.